Mycobacterium abscessus

Mycobacterium abscessus is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

MICROBIOLOGY

  • Human mycobacterial pathogen, occasional environmental contaminant. Present in water, sewerage, vegetation.
  • Considered among the most pathogenic and chemotherapy-resistant of rapid-growing Mycobacteria.
    • The organism produces clavulanate-insensitive broad-spectrum β-lactamase that limits the in vivo efficacy of β-lactams[10].
    • Culture on both solid and liquid media preferred to increase sensitivity.
      • CLSI recommends 7H10 and 7H11 solid media at 36°C for slow growers (and 28°C for rapid growers).
        • Some use Löwenstein-Jensen slants as the most sensitive media.
      • Typically, respiratory specimens treated with 0.25% N-Acetyl-L-cysteine and 1% NaOH for decontamination.
    • As a reminder,
      • Mycobacteria spp. divided into rapid growers (< 7 days) and slow growers (>7 days) based on time to mature growth on agar plates.
      • Rapid growers (often 3-7d): M. abscessus, also M. fortuitum: (3-7 days), M. chelonae.
      • Slow growers (> 7-10d): M. gordonae(7-10 days), M. malmoense, M. marinum; M. ulceransandM. xenopi(3-8 wks in Cx), M. terrae, M. nonchromogenicum, (also:M. kansasii, M. avium-intracellulare, M. tuberculosis)
  • Formerly part of "M. chelonae-complex", but important to distinguish from M. chelonae as antimycobacterial therapy more difficult with M. abscessus senso strictu.
    • Three human subspecies have been proposed: molecular identification (e.g., hsp65 or rpoB gene-based typing necessary to distinguish) recommended; usual biochemical/phenotypic methods fail. Speciation is difficult and there is not uniformity in recognition, so confusion is not infrequent when applying labels to M. abscessus isolates.
      • M. abscessus subsp. abscessus
        • Seen more commonly in North America
        • Many isolates have mutational resistance or inducible resistance re: function erm gene.
        • Resistance often is seen after the 3-14d employment of macrolide.
          • Testing of isolates for inducible macrolide resistance suggested.
          • Prior exposure to macrolides heightens the likelihood of macrolide resistance.
        • ~20% of M. abscessus subsp abscessus isolates contain an inactive erm gene.
          • If so, this translates into an improved chance of success the chances of a successful treatment outcome with macrolide-based therapy
      • M. abscessus subsp. massiliense
        • Lacks inducible macrolide resistance or erm gene[15](non-functional)
        • More frequently seen in Korea.
      • M. abscessus subsp. bolletii°
        • May have an inducible erm gene.
      • The first two species represent most human infections.
  • Occasionally confused with Corynebacterium spp. (described as diphtheroid growing in broth systems).
  • In vitro resistance rates (most studies from Asia):

-- To view the remaining sections of this topic, please or --

MICROBIOLOGY

  • Human mycobacterial pathogen, occasional environmental contaminant. Present in water, sewerage, vegetation.
  • Considered among the most pathogenic and chemotherapy-resistant of rapid-growing Mycobacteria.
    • The organism produces clavulanate-insensitive broad-spectrum β-lactamase that limits the in vivo efficacy of β-lactams[10].
    • Culture on both solid and liquid media preferred to increase sensitivity.
      • CLSI recommends 7H10 and 7H11 solid media at 36°C for slow growers (and 28°C for rapid growers).
        • Some use Löwenstein-Jensen slants as the most sensitive media.
      • Typically, respiratory specimens treated with 0.25% N-Acetyl-L-cysteine and 1% NaOH for decontamination.
    • As a reminder,
      • Mycobacteria spp. divided into rapid growers (< 7 days) and slow growers (>7 days) based on time to mature growth on agar plates.
      • Rapid growers (often 3-7d): M. abscessus, also M. fortuitum: (3-7 days), M. chelonae.
      • Slow growers (> 7-10d): M. gordonae(7-10 days), M. malmoense, M. marinum; M. ulceransandM. xenopi(3-8 wks in Cx), M. terrae, M. nonchromogenicum, (also:M. kansasii, M. avium-intracellulare, M. tuberculosis)
  • Formerly part of "M. chelonae-complex", but important to distinguish from M. chelonae as antimycobacterial therapy more difficult with M. abscessus senso strictu.
    • Three human subspecies have been proposed: molecular identification (e.g., hsp65 or rpoB gene-based typing necessary to distinguish) recommended; usual biochemical/phenotypic methods fail. Speciation is difficult and there is not uniformity in recognition, so confusion is not infrequent when applying labels to M. abscessus isolates.
      • M. abscessus subsp. abscessus
        • Seen more commonly in North America
        • Many isolates have mutational resistance or inducible resistance re: function erm gene.
        • Resistance often is seen after the 3-14d employment of macrolide.
          • Testing of isolates for inducible macrolide resistance suggested.
          • Prior exposure to macrolides heightens the likelihood of macrolide resistance.
        • ~20% of M. abscessus subsp abscessus isolates contain an inactive erm gene.
          • If so, this translates into an improved chance of success the chances of a successful treatment outcome with macrolide-based therapy
      • M. abscessus subsp. massiliense
        • Lacks inducible macrolide resistance or erm gene[15](non-functional)
        • More frequently seen in Korea.
      • M. abscessus subsp. bolletii°
        • May have an inducible erm gene.
      • The first two species represent most human infections.
  • Occasionally confused with Corynebacterium spp. (described as diphtheroid growing in broth systems).
  • In vitro resistance rates (most studies from Asia):

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: November 7, 2020